Skip to content
Back to full profile

Oral selective estrogen-receptor degrader (SERD)

Camizestrant

Etcamah · CAMI

Oral selective estrogen-receptor degrader (SERD) · approved 2026 · 10 references

An oral SERD switched in for the aromatase inhibitor when an ESR1 mutation appears in circulating tumor DNA. The kidney story belongs to its CDK4/6 partner: camizestrant does not block creatinine secretion, and its own arm had fewer creatinine rises than the comparator.

Signature injury
Prerenal / Hemodynamic AKI
Severity
Mild
Reversibility
Reversible
Onset
No drug-specific renal onset window exists, because no renal lesion is attributed to the drug. The time course that matters is cardiac: mean heart rate fell by about 13 beats per minute with the largest fall on Day 15, bradycardia adverse events had a median onset of 17 days, and the label front-loads ECGs into the first 2 weeks. A creatinine change follows its own precipitant - CDK4/6-inhibitor diarrhea, intercurrent illness, a co-administered nephrotoxin - on that cause's timeline.

Kidney summary

Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.

Renal dosing
Not in the atlas's table of label-specified renal dose changes; the Dosing section has the full entry.
Hemodialysis
Not removed by hemodialysis
Not studied in kidney failure; with an apparent volume of distribution of 1,888 L, a ~23-hour half-life and 4.8% of a dose excreted unchanged in urine (FDA label), intermittent hemodialysis would reach very little of the body burden. No post-dialysis dose is defined, and the label calls the effect of CLcr <30 and ESKD on exposure unknown.
The atlas summary. Full prose in the Dialyzability section.
FDA boxed warning
Yes
Label: ETCAMAH, Sep 2026. Not necessarily about the kidney. FDA label section.

Signature kidney injury & incidence

Prerenal / Hemodynamic AKI.

No renal lesion is attributed to camizestrant, and SERENA-6's comparator arm is what lets that be said rather than assumed. Every patient in the trial took a CDK4/6 inhibitor, and in the FDA label's laboratory table creatinine increased from baseline in 16% of patients on camizestrant with a CDK4/6 inhibitor (grade 3-4 0.6%; N=155) against 20% on an aromatase inhibitor with a CDK4/6 inhibitor (grade 3-4 1.3%; N=155) - lower on the camizestrant arm. The label also reports that camizestrant does not inhibit the tubular creatinine transporters OCT2, MATE1 or MATE2-K in vitro, so the creatinine rise clinicians see on this regimen is best read as the CDK4/6 inhibitor's. The label has no renal warning; its boxed warning is arrhythmia risk with QTc-prolonging drugs. SERENA-6 is published (Bidard, N Engl J Med 2025), but the renal laboratory rows come from the label.

Source: No drug-attributable renal incidence: creatinine increased 16% all-grade / 0.6% grade 3-4 on camizestrant + CDK4/6 inhibitor (N=155) versus 20% / 1.3% on aromatase inhibitor + CDK4/6 inhibitor (N=155), FDA label SERENA-6 laboratory table

Reported injury signatures: Prerenal / Hemodynamic AKI.

Mechanism of kidney injury

No direct nephrotoxic mechanism is established, and the label's in vitro transporter data argue against the one the regimen is known for. Camizestrant is cleared mainly by CYP3A and UGT1A4 metabolism: after a radiolabelled 75 mg dose, 65% of radioactivity was recovered in feces (14.5% unchanged) and 17% in urine (4.8% unchanged). In vitro it inhibits P-gp, BCRP and OATP1B1 but does not inhibit OCT2, OAT1, OAT3, MATE1 or MATE2-K - the proximal-tubule transporters whose blockade by abemaciclib raises serum creatinine without lowering true GFR. Its cardiac effects are pharmacological: a nonclinical study attributes the dose-dependent fall in heart rate to reduced sinoatrial-node pacemaker (HCN4 'funny') current, and the label's boxed warning concerns QTc prolongation with ribociclib or other QTc-prolonging drugs. The kidney enters that story through the electrolytes, not through a lesion: the label directs that electrolyte abnormalities be assessed and corrected before the first dose and during treatment.

Clinical presentation

There is no characteristic renal presentation. The likeliest renal finding is a modest, stable creatinine rise that arrived with the CDK4/6 inhibitor - most often abemaciclib - and persists after the switch, with a normal urinalysis and no change in cystatin C. Diarrhea is the partner's other renal route: in the SERENA-1 combination cohorts it was the commonest adverse event with abemaciclib (87.5% at camizestrant 75 mg), and volume or potassium loss from it matters twice on this drug, once for prerenal physiology and once for the QTc. Corrected calcium decreased from baseline in 17% of camizestrant-arm patients against 12% on the comparator, none of them grade 3 or 4, in a regimen whose ECG requirements make the calcium worth knowing.

Management

No camizestrant-specific renal management exists, because no renal lesion is attributed to it. A creatinine rise on the regimen calls first for the question of when it began: a rise dating to the start of abemaciclib or another CDK4/6 inhibitor, stable, with a bland urinalysis and an unchanged cystatin C-based eGFR, is the partner's secretion effect and needs no dose change. Before reducing the dose of a renally cleared co-medication on the strength of that rise, confirm it with a cystatin C-based estimate. A rise that is new, progressive or accompanied by proteinuria, hematuria or an active sediment needs its own workup - volume status after diarrhea, obstruction, contrast, an interacting drug - before either drug is blamed. Camizestrant's label recommends no dose reductions for adverse reactions; it is withheld for QTc prolongation, symptomatic bradycardia, grade 2 or higher visual disturbance or other grade 3 or higher reactions, and the CDK4/6 inhibitor is managed by its own label.

Risk factors

  • Abemaciclib as the CDK4/6 partner: it blocks tubular creatinine secretion and causes frequent diarrhea, the regimen's two routes to a creatinine rise
  • Hypokalemia, hypomagnesemia or hypocalcemia, which add to the QTc risk the boxed warning describes, especially with diarrhea on abemaciclib
  • Ribociclib as the CDK4/6 partner: it prolongs the QTc itself and, as a strong CYP3A inhibitor, roughly doubles camizestrant exposure
  • Creatinine clearance below 30 mL/min or end-stage kidney disease - the label states the effect on camizestrant pharmacokinetics there is unknown
  • Baseline bradycardia or heart-rate-lowering co-medication such as beta-blockers, since the label asks for more frequent heart-rate checks in the first 30 days

Prevention

  • Assess and correct electrolyte abnormalities before the first dose, as the boxed warning directs, so a low potassium, magnesium or calcium does not compound the QTc risk
  • Obtain an ECG before starting and avoid adding other QTc-prolonging or heart-rate-lowering drugs where alternatives exist
  • Replace fluid and electrolytes promptly when CDK4/6-inhibitor diarrhea starts, which protects both against prerenal azotemia and against a potassium drop that raises arrhythmia risk

Renal dose adjustment

No renal dose adjustment is recommended or defined. The label has no renal-impairment subsection; its pharmacokinetics section reports no clinically significant differences at creatinine clearance 30 to below 90 mL/min (modified Cockcroft-Gault), and states that the effect of clearance 15 to below 30 mL/min and of end-stage kidney disease is unknown. The dose is 75 mg once daily and the label recommends no dose reductions for adverse reactions. The dose changes it does make are for severe hepatic impairment and for CYP3A inducers, and both depend on which CDK4/6 inhibitor is the partner - 75 mg every other day in severe (Child-Pugh C) hepatic impairment when the partner is the one CDK4/6 inhibitor that strongly inhibits CYP3A, and 150 mg once daily alongside an unavoidable moderate CYP3A inducer when the partner is either of the other two.

Dialyzability & ESKD dosing

Not studied, and unlikely to be meaningfully removed. The label gives an apparent volume of distribution of 1,888 L and a terminal half-life of about 23 hours, and only 4.8% of a dose appears unchanged in urine, so intermittent hemodialysis would reach a very small fraction of the body burden. No post-dialysis timing or supplemental dose is defined, and because end-stage kidney disease was not characterized, use in dialysis patients rests on that inference rather than on measured data. Peritoneal dialysis and CRRT are not characterized.

Differential diagnosis

The partner drug comes first. A creatinine rise on camizestrant plus abemaciclib is, until shown otherwise, abemaciclib's blockade of tubular creatinine secretion - the CDK4/6-inhibitor literature finds most such rises are pseudo-AKI on cystatin C. After that, work the usual differential for a patient with metastatic breast cancer: prerenal physiology from diarrhea or poor intake, obstruction from nodal or retroperitoneal disease, hypercalcemia from bone metastases, contrast, and nephrotoxic co-medications. Camizestrant itself is not a tubular, interstitial or glomerular toxin on present evidence, and the trial's comparator arm - more creatinine rises without it - argues against attributing one to it.

Monitoring

  • ECG before the first dose, weekly for the first 2 weeks and periodically thereafter, per the label
  • Serum electrolytes at baseline and during treatment as clinically indicated, per the label - in practice potassium, magnesium and calcium, the QTc-relevant ones - with closer checks during CDK4/6-inhibitor diarrhea
  • Heart rate more often in the first 30 days if baseline rate is under 60 beats per minute or the patient takes a heart-rate-lowering drug
  • Serum creatinine with a cystatin C-based estimate when creatinine rises, to separate the partner drug's secretion effect from true GFR loss
  • Visual symptoms at each visit, since grade 2 or higher visual disturbance is a reason to withhold the drug

Key trials & series

  • SERENA-6 (NCT04964934; phase 3, double-blind, placebo-controlled) - 3,256 patients on first-line aromatase inhibitor plus CDK4/6 inhibitor were tested for ESR1 mutations in circulating tumor DNA, and 315 with an emerging mutation and no radiological progression were randomized to switch to camizestrant 75 mg with continued CDK4/6 inhibitor or to stay on the aromatase inhibitor. Median progression-free survival was 16.0 versus 9.2 months at the interim analysis (Bidard, N Engl J Med 2025) and 16.8 versus 9.2 months at extended follow-up (Turner, Lancet Oncol 2026). Neither paper's abstract reports a renal laboratory row; the label's creatinine comparison comes from this trial's 155-patient safety arms.
  • SERENA-1 combination cohorts (Baird, Clin Cancer Res 2025) - phase 1 camizestrant with abemaciclib, palbociclib or ribociclib in pretreated disease; diarrhea dominated with abemaciclib (87.5% at 75 mg) and neutropenia with palbociclib and ribociclib. No renal endpoint.
  • SERENA-1 monotherapy (Hamilton, Ann Oncol 2024) - dose escalation from 25 to 450 mg in 108 patients; visual effects (56%) and sinus bradycardia (44%) were the commonest treatment-related events, with no grade 3 or higher treatment-related events at 150 mg or below. No renal endpoint.
  • SERENA-2 (Oliveira, Lancet Oncol 2024) - randomized phase 2 of camizestrant 75 or 150 mg versus fulvestrant after prior endocrine therapy (240 patients); median progression-free survival 7.2 and 7.7 versus 3.7 months. No renal endpoint.

Clinical pearls

  • Two arms, same CDK4/6 inhibitor, more creatinine rises on the arm without camizestrant: 20% against 16%. That comparison is the reason no lesion is attributed to the drug.
  • Camizestrant does not inhibit OCT2, MATE1 or MATE2-K. If creatinine rose with abemaciclib and stays up after the switch, it is still abemaciclib's.
  • The kidney's job on this drug is electrolytes. The boxed warning asks for them to be corrected before the first dose and kept normal, and abemaciclib diarrhea is the commonest way they fall.
  • Ribociclib doubles camizestrant exposure and prolongs the QTc on its own - the combination behind the boxed warning and the one Torsades de Pointes case in dose-finding.
  • There is no renal dose adjustment, but there is also no data below creatinine clearance 30 or in end-stage kidney disease. 'Not studied' is not 'safe'.

Anticancer mechanism

Oral selective estrogen-receptor degrader (SERD) and complete estrogen-receptor antagonist that binds estrogen receptor alpha, including the ESR1-mutant receptor that confers resistance to aromatase inhibitors, and drives its degradation. Given as 75 mg orally once daily with a CDK4/6 inhibitor (abemaciclib, palbociclib or ribociclib) that is continued at the dose the patient was already taking. The September 2026 approval is an accelerated approval based on progression-free survival measured from detection of the ESR1 mutation, and selection requires an FDA-authorized plasma test repeated every 3 months during first-line therapy.

Guidelines & consensus

Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.

  • ADQI (2026) — The nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroupProvides expert-based statements (modified Delphi) on preventing and managing cisplatin/platinum-associated AKI, including isotonic IV hydration, attention to volume status and concomitant nephrotoxins, and incorporates evidence that IV magnesium supplementation may reduce cisplatin-associated AKI; emphasizes risk stratification and standardized AKI definitions.Nat Rev Nephrol · PMID 41361704
  • SIRM (2022) — SIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM)Recommends eGFR-based renal risk assessment and pre/post-contrast isotonic saline or sodium bicarbonate hydration; advises maintaining a 5-7 day interval between iodinated contrast administration and cisplatin in cancer patients to reduce additive nephrotoxicity.Radiol Med · PMID 35303246
  • KDIGO (2020) — KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancerIdentifies platinum compounds (especially cisplatin) as leading cytotoxic causes of acute tubular injury, AKI, and electrolyte/magnesium wasting; calls for interdisciplinary onco-nephrology care, accurate GFR estimation, and individualized drug dosing in patients with reduced kidney function.Kidney Int · PMID 33126977
  • KDIGO (2020) — KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantationAddresses chemotherapy-associated AKI/CKD in hematologic cancer, GFR estimation and chemotherapy dosing in patients with reduced kidney function, and management priorities and research gaps for onco-nephrology care.Kidney Int · PMID 33276867
  • ADDIKD (2025) — Integrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practiceProvides GRADE-based, drug-specific dose-adjustment recommendations for anticancer agents in kidney dysfunction (illustrated for methotrexate, cisplatin, carboplatin and nivolumab); the recommendations build on Part 1's standardised CKD-EPI eGFR assessment rather than Cockcroft-Gault creatinine clearance.EClinicalMedicine · PMID 40290844
  • ADDIKD (2025) — Aligning kidney function assessment in patients with cancer to global practices in internal medicineThree consensus recommendations: assess kidney function by GFR (measured GFR or CKD-EPI eGFR), classify it using KDIGO categories, and use this uniform approach to dose anticancer drugs — moving cancer medicine away from Cockcroft-Gault estimated creatinine clearance.EClinicalMedicine · PMID 40290845
  • ADDIKD (2025) — A methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney functionEstablishes that, where RCT evidence is lacking, anticancer drug dosing recommendations in kidney dysfunction should be derived by critically appraising observational literature via GRADE combined with structured international multidisciplinary consensus voting.EClinicalMedicine · PMID 40290846
  • KDIGO (2013) — Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)Defines/stages AKI by serum creatinine and urine output; emphasizes avoiding nephrotoxins, maintaining euvolemia/perfusion, dose-adjusting drugs to kidney function, and monitoring high-risk patients — the framework applied to nephrotoxic anti-cancer agents.Crit Care · PMID 23394211
  • KDIGO (2024) — Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknownsEvaluate and risk-stratify CKD, manage to delay progression and its complications, and practise explicit medication management and drug stewardship — the framework the atlas's G1–G5 eGFR banding and every renal dose-adjustment recommendation sit inside. Because the guideline excludes dialysis and transplant recipients by its own statement of scope, its recommendations do not carry to those settings, where this atlas's dialyzability and post-transplant guidance rests on other sources.Kidney Int · PMID 38519239
  • KDIGO (2021) — Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular DiseasesProvides the staging/treatment framework for drug-associated glomerular lesions (e.g., bisphosphonate- and interferon-related collapsing FSGS, VEGF-inhibitor podocytopathy/proteinuria), including immunosuppression and supportive RAAS-blockade strategies.Kidney Int · PMID 34556300
  • KDIGO (2024) — Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated VasculitisUpdates immunosuppressive induction (rituximab/cyclophosphamide), incorporates avacopan and lower-dose or glucocorticoid-sparing regimens — the management framework for drug- and checkpoint-inhibitor-associated ANCA/pauci-immune glomerulonephritis.Kidney Int · PMID 38388147
  • KDIGO (2024) — Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus NephritisUpdates first-line lupus nephritis therapy to combination immunosuppression with the addition of belimumab or a calcineurin inhibitor (voclosporin) — informs management of immune-complex/lupus-like glomerulonephritis encountered with immunotherapy.Kidney Int · PMID 38182299
  • KDIGO (2025) — Executive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)Encourages liberal kidney biopsy and stricter proteinuria control (<0.5 g/d, ideally <0.3 g/d) with RAAS blockers, SGLT2 inhibitors, and targeted-release budesonide — the framework for IgA-dominant glomerular lesions, including those triggered by immune-modulating cancer therapy.Kidney Int · PMID 40975525

References

10 peer-reviewed references. Citation metadata via PubMed / NLM.

  1. 1.First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer.Bidard FC et al. · N Engl J Med · 2025 · PMID 40454637
  2. 2.Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial.Turner NC et al. · Lancet Oncol · 2026 · PMID 42442380
  3. 3.Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2- Advanced Breast Cancer: Results from SERENA-1.Baird RD et al. · Clin Cancer Res · 2025 · PMID 40788187
  4. 4.A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results.Hamilton E et al. · Ann Oncol · 2024 · PMID 38729567
  5. 5.Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial.Oliveira M et al. · Lancet Oncol · 2024 · PMID 39481395
  6. 6.Camizestrant-induced heart rate reduction is mediated via a sinoatrial node pacemaker channel mechanism.Hall A et al. · Toxicol Appl Pharmacol · 2026 · PMID 41903809
  7. 7.Renal adverse events associated with cyclin-dependent kinase 4/6 inhibitors.Izzedine H et al. · Cancer Treat Rev · 2025 · PMID 41385991
  8. 8.Pseudo acute kidney injury in patients receiving CDK4/6 inhibitors.Buijs SM et al. · Br J Cancer · 2025 · PMID 39930149
  9. 9.The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance.Lawson M et al. · Cancer Res · 2023 · PMID 37725704
  10. 10.Camizestrant: First Approval.Lee A · Drugs · 2026 · PMID 42786359
Educational monograph from NephTox (nephtox.com). Not medical advice — verify against current guidelines before any clinical decision.